Filed in archive
Cancer
, FDA Approvals
, Treatment
by Gloria Gamat on October 30, 2007
Novartis Pharma's Tasigna (nilotinib) has recently been approved by the US FDA for the treatment of Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients whose disease has progressed on or who cannot tolerate other therapies that included imatinib (Gleevec).
The abnormal chromosome called the Philadelphia chromosome is located in the leukemic cells and is present in the majority of CML patients. CML accounts for 15 percent of all leukemias in adults.
Find more details from the FDA News.
FDA's approval of Tasigna includes a black box warning for possible life-threatening heart problems that may lead to an irregular heartbeat and possible sudden death.
The effectiveness of Tasigna is based on response rates observed in an ongoing clinical trial. Responses are associated with normalization of blood counts and bone marrow examinations. Further follow-up of patients is needed to determine how long these responses will last.
The abnormal chromosome called the Philadelphia chromosome is located in the leukemic cells and is present in the majority of CML patients. CML accounts for 15 percent of all leukemias in adults.
Find more details from the FDA News.
Tags:
Tasigna
nilotinib
philadelphia
chromosome
positive
chronic
myeloid
leukemia
CML
health
philadelphia+
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/99708
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Tasigna (nilotinib), FDA-Approved for Philadelphia Chromosome Positive CML:
|
Rating: 6.33 out of 3 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
